Atlas Trials

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Clinical trial NCT05827614 · TERMINATED

Trial details

NCT number
NCT05827614
Sponsor
Boundless Bio, Inc.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Triple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CarcinomaHigh Grade Endometrial CarcinomaAnogenital CancerHead and Neck (HNSCC)Cutaneous Squamous Cell Carcinoma (CSCC)Cervical Squamous Cell CarcinomaER+ Breast CancerLeiomyosarcoma (LMS)Undifferentiated Pleomorphic Sarcoma (UPS)Pancreatic Cancer MetastaticSmall Cell Lung Cancer
Start date
2023-03-24
Primary completion
2026-03-17
Enrollment
85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.